Skip to main content

Table 1 Survival by risk groups of 356 patients treated with HD IL-2 alone

From: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

  Favorable Intermediate Poor
Median OS (months) (95% CI) 64.5 (39.4–112) 57.6 (34.5–62) 14 (4–58)
2 year OS from IL-2 treatment 73.8% 63.7% 39.8%
  1. OS overall survival, 95% CI 95% confidence intervals, HD high dose, IL-2 Interleukin-2